1. Home
  2. GROV vs LITS Comparison

GROV vs LITS Comparison

Compare GROV & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

HOLD

Current Price

$1.54

Market Cap

50.9M

ML Signal

HOLD

LITS

Lite Strategy Inc.

N/A

Current Price

$1.07

Market Cap

48.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GROV
LITS
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.9M
48.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GROV
LITS
Price
$1.54
$1.07
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$1.60
N/A
AVG Volume (30 Days)
60.0K
478.3K
Earning Date
03-10-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$180,808,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.95
52 Week High
$1.84
$9.00

Technical Indicators

Market Signals
Indicator
GROV
LITS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GROV
LITS

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: